Toyota Kazuhiro, Murakami Yoshiaki, Kondo Naru, Uemura Kenichiro, Nakagawa Naoya, Takahashi Shinya, Sueda Taijiro
Department of Surgery, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, Hiroshima, 734-8551, Japan.
J Gastrointest Surg. 2017 Jun;21(6):990-999. doi: 10.1007/s11605-017-3407-0. Epub 2017 Mar 24.
Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein that influences chemotherapy effectiveness and prognosis. The aim of this study was to investigate whether SPARC expression correlates with the postoperative survival of patients treated with surgical resection for biliary carcinoma.
SPARC expression in resected biliary carcinoma specimens was investigated immunohistochemically in 175 patients. The relationship between SPARC expression and prognosis after surgery was evaluated using univariate and multivariate analyses.
High SPARC expression in peritumoral stroma was found in 61 (35%) patients. In all patients, stromal SPARC expression was significantly associated with overall survival (OS) (P = 0.006). Multivariate analysis revealed that high stromal SPARC expression was an independent risk factor for poor OS (HR 1.81, P = 0.006). Moreover, high stromal SPARC expression was independently associated with poor prognosis in a subset of 118 patients treated with gemcitabine-based adjuvant chemotherapy (HR 2.04, P = 0.010) but not in the 57 patients who did not receive adjuvant chemotherapy (P = 0.21).
Stromal SPARC expression correlated with the prognosis of patients with resectable biliary carcinoma, and its significance was enhanced in patients treated with adjuvant gemcitabine-based chemotherapy.
富含半胱氨酸的酸性分泌蛋白(SPARC)是一种基质细胞蛋白,影响化疗效果和预后。本研究旨在探讨SPARC表达与接受手术切除的胆管癌患者术后生存率是否相关。
对175例患者手术切除的胆管癌标本进行免疫组织化学检测,分析SPARC表达情况。采用单因素和多因素分析评估SPARC表达与术后预后的关系。
61例(35%)患者肿瘤周围基质中SPARC高表达。在所有患者中,基质SPARC表达与总生存期(OS)显著相关(P = 0.006)。多因素分析显示,基质SPARC高表达是OS不良的独立危险因素(HR 1.81,P = 0.006)。此外,在接受吉西他滨辅助化疗的118例患者亚组中,基质SPARC高表达与预后不良独立相关(HR 2.04,P = 0.010),而在未接受辅助化疗的57例患者中则无相关性(P = 0.21)。
基质SPARC表达与可切除胆管癌患者的预后相关,在接受吉西他滨辅助化疗的患者中其意义更为显著。